In recent years, population studies associating sodium intake with morbidity and mortality have contributed to the evidence of sodium reduction as a prophylaxis initiative, although not unambiguously, as the interpretations of the population studies have been conflicting. 1,2 In addition, recent studies have shown a harmful effect of sodium reduction on patients with established heart failure 3,4 and diabetes. 5, 6 Hitherto, the recommendation to reduce sodium intake is based on the effect on a surrogate marker, i.e., blood pressure (BP), and on the hypothetical benefits in terms of reduction in cardiovascular morbidity and mortality. [7] [8] [9] There is evidence from several published reviews of randomized studies [10] [11] [12] [13] [14] [15] [16] and other Cochrane reviews 17,18 of the effects of reduced sodium intake on BP. In addition sodium intake has been shown to affect other surrogate markers, such as the renin−angiotensin−aldosterone system, catecholamines, and serum lipids. The present review represents a second update of the first cumulative meta-analysis that includes an analysis of hormones and lipids in addition to BP, 14 first updated in 2003. 19 The purpose of the present review was to estimate the influence of low-vs. high-dietary sodium intake on systolic BP (SBP), diastolic BP (DBP), mean BP (MBP), and blood concentrations of renin, aldosterone, catecholamines, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride to contribute to the evaluation of the possible suitability of sodium reduction as a prophylaxis initiative and treatment of hypertension.
In recent years, population studies associating sodium intake with morbidity and mortality have contributed to the evidence of sodium reduction as a prophylaxis initiative, although not unambiguously, as the interpretations of the population studies have been conflicting. 1, 2 In addition, recent studies have shown a harmful effect of sodium reduction on patients with established heart failure 3,4 and diabetes. 5, 6 Hitherto, the recommendation to reduce sodium intake is based on the effect on a surrogate marker, i.e., blood pressure (BP), and on the hypothetical benefits in terms of reduction in cardiovascular morbidity and mortality. [7] [8] [9] There is evidence from several published reviews of randomized studies [10] [11] [12] [13] [14] [15] [16] and other Cochrane reviews 17, 18 of the effects of reduced sodium intake on BP. In addition sodium intake has been shown to affect other surrogate markers, such as the renin−angiotensin−aldosterone system, catecholamines, and serum lipids. The present review represents a second update of the first cumulative meta-analysis that includes an analysis of hormones and lipids in addition to BP, 14 first updated in 2003. 19 The purpose of the present review was to estimate the influence of low-vs. high-dietary sodium intake on systolic BP (SBP), diastolic BP (DBP), mean BP (MBP), and blood concentrations of renin, aldosterone, catecholamines, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride to contribute to the evaluation of the possible suitability of sodium reduction as a prophylaxis initiative and treatment of hypertension.
Methods
Types of studies, participants, and interventions. Randomized controlled trials allocating persons with normal or elevated BP irrespective of race and age to either a low-or a high-sodium diet and in which the sodium intake was estimated by the 24-h urinary sodium excretion (either measured on the basis of a 24-h urine collection, or estimated from a sample of at least 8 h). Studies systematically investigating unhealthy patients with other diseases than elevated BP were excluded.
1. the sample size (N); 2. the mean age of participants; 3. the fraction of females, males; Caucasians, blacks, and Asians; 4. the duration of the intervention; 5. the sodium reduction measured as the difference between 24-h urinary sodium excretion during low-sodium and high-sodium diets and s.d.; 6. SBP (s.d.) and DBP (s.d.) before and after intervention; 7. difference between changes in SBP and DBP obtained during low-sodium and high-sodium diets and the s.d. of these differences; 8. for crossover studies, when possible, the overall effect estimate and s.e.; 9. levels of hormones and lipids in the blood and their s.d.
during low-sodium and high-sodium diets. Concerning lipids, cholesterol units of mmol/l were transformed to mg/dl by means of the factor 38.6 and triglyceride units of mmol/l were transformed to mg/dl by means of the factor 88.4.
If there were discrepancies between reviewers they looked at the data together and came to an agreement.
Assessment of risk of bias in included studies:
This was performed using the Cochrane risk of bias tool, including recording of allocation, blinding, incomplete outcome data, and selective reporting. Subgroup analyses were performed for contrasting sources of bias appearing from the risk of bias analysis.
Measures of treatment effect: This was defined as the mean difference (MD) between the changes from baseline to end of treatment during a low-and a high-sodium diet. When units within an analysis were different the standardized MD (SMD) was used.
Unit of analysis issues
BP: Combined analyses were performed including both parallel and crossover studies. The generic inverse variance data type was used to analyze the effect in order to ensure that the weight of the crossover studies was not underestimated compared with the parallel studies.
Hormones and lipids: The very few parallel studies were excluded and the large fraction of crossover studies was analyzed separately.
Dealing with missing data: If s.d. was not reported it was calculated from a given s.e., 95% confidence interval (CI), P value or t value, estimated from a figure or imputed from the formula s.d. (change) = sq root (SD1sq + SD2sq), where SD1 is s.d. on BP before intervention and SD2 is s.d. on BP after intervention.
Assessment of heterogeneity: A χ 2 -test included in the forest plot was used to assess whether observed differences in results are compatible with chance alone. A low P value (or a large χ 2 statistic relative to its degree of freedom) provides evidence of heterogeneity of intervention effects (variation in effect estimates beyond chance).
Assessment of reporting biases: Funnel plots were assessed for asymmetry.
Data synthesis: The weighted MD (WMD) was calculated for outcome measures with identical units in the included studies (BP, adrenaline, and lipids, after transformation). The SMD was calculated for outcome measures with different units (renin, aldosterone, and noradrenaline). If P was <0.05 in the test for heterogeneity, a random effect analysis was carried out. In the homogeneous meta-analyses the fixed effect model was used.
Subgroup analysis
All analyses: subgroup analyses were performed for studies with duration of 2 weeks or more (hormones and lipids) and 4 weeks or more (all).
Lipids: subgroup analyses were performed for studies reducing sodium chloride intake to moderate levels (45 mmol or more).
Sensitivity analysis: Sensitivity analyses were performed excluding studies giving rise to asymmetry in the funnel plots.
results description of studies
One hundred and sixty seven references were identified and included in the review. In the studies of persons with elevated BP the median of the mean ages was 51 years (range ; the median duration was 28 days (4-365). The mean of the mean 24-h sodium excretions in the high salt intake groups was 196 mmol and in the low-salt intake groups was 71 mmol, corresponding to a mean sodium reduction of 125 mmol, and the median of mean sodium reductions was 94 mmol/24 h (10-90 percentiles: 46-236). In the studies of persons with normal BP, the median of mean ages was 27 years (range ; the median duration was 7 days (4-1,100). The mean of the mean 24-h sodium excretions in the high-salt intake groups was 201 mmol and in the low-salt intake groups was 50 mmol, corresponding to a mean sodium reduction of 150 mmol, and the median of mean sodium reductions was 146 mmol/24 h (10-90 percentiles: 56-246). In 100 studies including 7,005 participants there was information of the baseline 24-h sodium excretion, not influenced by diets. This was 157 mmol (10-90 percentiles: .
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risk of bias in included studies
The obligatory trial quality criterion was randomization. Double-blind, single-blind, or open studies with a parallel or a crossover design were accepted. A study was defined as single blind if an investigator measured BP without knowledge of the diet or by a computerized manometer and as open if precautions to decrease observer bias were not mentioned. Only 10 studies 49, 83, 86, 104, 127, 128, 134, 179, 181, 182 sufficiently explained the allocation concealment and only two studies used the intention to treat principle. 86, 127 We found two important contrasts: General blinding and blinding of outcome detection. We performed subanalyses of BPs in whites, both normotensive and hypertensive populations, but not in blacks and Asians due to the small numbers of trials. There were no differences in studies of low-bias risk vs. studies of high-bias risk: We did not perform subanalyses on the biochemical outcomes (hormones and lipids) as they are supposed to be performed blindly in 100% of cases. Table 2) .
In a meta-analysis of 28 normotensive trials (31 comparisons) in which MBP was measured, the mean weighted difference (WMD) of MBP was 0.00 (95% CI: −0.34, 0.33) mm Hg (P = 0.99) ( Table 3 ). In 13 trials (14 comparisons) in which only MBP was measured, the change was +1.01 (95% CI: 0.39, 1.63) mm Hg (P = 0.001).
In the 74 trials (76 comparisons) of Caucasians with elevated BP, WMD was a decrease in SBP of −5.48 (95% CI: −6.53, −4.43) mm Hg (P < 0.00001) and in DBP of −2.75 (95% CI: −3.34, −2.17) mm Hg (P < 0.00001) ( Table 1) . In sub meta-analyses of 47 trials (49 comparisons) with duration of at least 4 weeks, WMD was a decrease in SBP of −5.18 (−6.43, −3.94) mm Hg (P = 0.0001) and in DBP of −2.59 (95% CI: −3.32, −1.85) mm Hg (P = 0.00001) ( Table 2) .
In a meta-analysis of 21 hypertensive trials (23 comparisons) in which MBP was measured, the mean weighted difference (WMD) of MBP was −3.56 (95% CI: −4.07, −3.06) mm Hg (P = 0.00001) ( Table 3 ). In 5 trials (7 comparisons) in which only MBP was measured, the change was −2.03 (95% CI: −3.00, −1.06) mm Hg (P = 0.0001).
BP in blacks.
In the meta-analyses of 6 trials (7 comparisons) of blacks with normal BP, WMD was a decrease in SBP of −4.02 (95% CI: −7.37, −0.68) mm Hg (P = 0.02) and in DBP of −2.01 (95% CI: −4.37, 0.35) mm Hg (P = 0.09) ( Table 4) .
In the meta-analyses of 8 trials (9 comparisons) of blacks with elevated BP, WMD was a decrease in SBP of −6.44 (95% Table 4) .
BP in Asians.
In the meta-analyses of 3 trials (3 comparisons) of Asians with normal BP, WMD was a decrease in SBP of −1.27 (95% CI: −3.07, 0.54) mm Hg (P = 0.17) and in DBP of −1.68 (95% CI: −3.29, −0.06) mm Hg (P = 0.04) ( Table 5 ).
In the meta-analyses of 7 trials (7 comparisons) of Asians with elevated BP, WMD was a decrease in SBP of −10.21 (95% CI: −16.98, −3.44) mm Hg (P = 0.003) and in DBP of −2.60 (95% CI: −4.03, −1.16) mm Hg (P = 0.0004) ( Table 5 ). 
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Renin. Two parallel trials were excluded 91, 147 (Tables 6 and 7 and Figure 3 ). In the remaining 70 crossover trials of measurement of renin (81 comparisons), the SMD of sodium reduction was 1.15 (95% CI: 0.99, 1.30) (Z = 14.81, P < 0.00001) (Figure 3) . In comparisons with duration of at least 2 weeks (n = 29) the SMD was 0.67 (95% CI 0.53, 0.82), P = 0.00001 and in comparisons with duration of at least 4 weeks (n = 14) the SMD was 0.47 (95% CI: 0.35, 0.60), P = 0.00001.
Aldosterone. Three parallel trials were excluded 91, 108, 147 (Tables 6 and 7 and Figure 4) . In the remaining 51 crossover trials of measurement of aldosterone (59 comparisons), Cholesterol. Three parallel trials were excluded 33, 89, 183 (Tables 8 and 9 and Figure 5 ). In the remaining 24 crossover trials of measurement of cholesterol (25 comparisons), WMD was an increase of 5.76 mg/dl (95% CI: 2.29, 9.24), P = 0.001 ( Figure 5 ). In comparisons with duration of at least 2 weeks (n = 13) WMD was 2.48 mg/dl (95% CI: −2.18, 7.14), P = 0.30 and in comparisons with duration of at least 4 weeks (n = 9), WMD was 3.21 mg/dl (95% CI: −2.51, 8.93), P = 0.27.
LDL.
One parallel trial was excluded 89 (Tables 8 and 9 ). In the remaining 15 crossover trials of measurement of LDL (16 comparisons), WMD was a nonsignificant increase of 2.88 mg/dl (95% CI: −1.03, 6.79), P = 0.15. In comparisons with duration 
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Effects of Low-Sodium Diet of at least 2 weeks (n = 8), WMD was 2.45 mg/dl (95% CI: −3.15, 8.06), P = 0.39 and in comparisons with duration of at least 4 weeks (n = 6), WMD was 3.72 mg/dl (95% CI: −2.67, 10.11), P = 0.25.
HDL.
Two parallel trials were excluded 89, 183 (Tables 8 and 9 ). In the remaining 17 crossover trials of measurement of HDL (18 comparisons), there was no effect of sodium reduction on serum HDL: WMD: 0.09 mg/dl (95% CI: −1.44, 1.62) P = 0.91. 
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This result did not change in comparisons with duration of at least 2 weeks (−0.61 mg/dl (−2.70, 1.47) (n = 10)) or at least 4 weeks (−0.14 mg/dl (−2.58, 2.30) (n = 8)).
Triglyceride. Two parallel trials were excluded 89, 183 (Tables 8 and  9 and Figure 6 ). In the remaining 18 crossover trials of measurement of triglyceride (19 comparisons) , WMD was an increase of 6.78 mg/dl (95% CI: 2.81, 10.75), P = 0.0008 (Figure 6 ).
In comparisons with duration of at least 2 weeks (n = 11) the effect was 7.78 mg/dl (95% CI: 2.23, 13.34), P = 0.006 and in comparisons with duration of at least 4 weeks (n = 7) the effect was 8.37 mg/dl (95% CI: −1.43, 18.18), P = 0.09. 
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Lipids. The funnel plots of all analyses were investigated. For each funnel plot all studies giving rise to asymmetry were eliminated. The resulting effect was compared with the original analysis. All these analyses showed only marginal effects without significance (data not shown).
discussion
This meta-analysis in general compares the effects of a dietary sodium intake which is <120 mmol with a sodium intake which is >150 mmol. The mean and the range of the baseline 24-h sodium excretion of the included populations before diet manipulation (157 mmol/24h (10-90 percentile: ) were within the range, which recently has been hypothesized to be physiologically determined. 188, 189 The effect on BP in normotensives increased marginally from −1.27/−0.05 to −1.29/−0.45 mm Hg, when only studies with duration of 4 weeks or more were included, whereas there was no difference in hypertensives (−5.41/−2.68 vs. −5.03/−2.47 mm Hg).
In the previous analysis, 14, 19 the adverse effects were not significant in the longer-term studies, of which, however, there were 
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Effects of Low-Sodium Diet very few. In the present analysis, the adverse effects on hormones and lipids are now significant or borderline significant also in the longer-term studies of at least 4 weeks (renin, aldosterone, adrenalin, and triglyceride). The long-term effect of sodium reduction on renin and aldosterone is in accordance with the findings of Oliver et al. in Yanomamo Indians, who ingest extremely small amounts of sodium. They had a 3 times higher level of renin in the blood and a 10 times higher excretion of aldosterone in the urine than did normal controls. 190 Thus, the present metaanalysis provides a possible explanation for the relatively small effect of reduced sodium intake on BP: Compensatory activation of the renin−aldosterone system is proportional to the degree of sodium reduction. Furthermore, the increases in noradrenaline and adrenaline may contribute to this counter-regulation. 191 The Dietary Approaches to Stop Hypertension (DASH) study 152 found a significantly higher effect of sodium reduction on BP than the present meta-analysis, but in white normotensives the effect on DBP was only 1.4 mm Hg. 192 The DASH finding of a higher effect in blacks prompted us to make a separate analysis on blacks and Asians. The analysis of blacks showed that the effect of sodium reduction in normotensive blacks corresponded to the one found in hypertensive blacks. This was in contradiction to the analyses of whites and Asians in whom the effect was smaller in normotensives than in hypertensives. However, compared with previous analyses, 14, 19 the diverging results within the black populations and between the black and white populations are smaller. Our cumulative meta-analysis 14 showed that up to 11 studies should be included before the result of the meta-analysis was stable, and in the beginning the effect was higher than the final effect. Consequently, it is probably too early to draw final conclusions about the effect of a lowvs. high-sodium diet in blacks and Asians. In whites, the results are still similar to the results from 1983. 14 Previous meta-analyses of randomized controlled trials with other selection criteria have shown similar results of sodium reduction on BP. 10, 13, 15, 16, 18, 20 Consequently, they confirm that selection of randomized controlled trials based on magnitude of sodium difference or duration of the intervention does not significantly change the overall effect size estimate. Consequently, major disagreements about this effect size no longer seem to exist. However, there is still significant disagreement regarding the relevance of the effect size, and the political salt conflict is still going strong. 193 Two recent papers exemplify this. 1, 2 In the meta-analysis of population studies by Strazzullo et al., 2 a statistically significant 20% increased risk of cerebrovascular 
Effects of Low-Sodium Diet death was found in persons with a high-salt intake compared with a low-salt intake. However, in a response letter to a critical comment 194 Strazzullo et al. accepted that the statistical significance depended on the inclusion of incomplete data from one of the population studies. Another review of the same studies concludes that low-salt intake in population studies is not associated with an improved morbidity or mortality. 1 This has recently been verified in a population study, which showed an inverse relationship between sodium intake and cardiovascular mortality. 195 Furthermore, the meta-analysis by Strazzullo et al. included two Asian population studies, in which the sodium intake in the high intake group was much higher than usually seen in Caucasians. If only American and European population studies had been included, there would be no difference between the high-salt intake and low-salt intake groups concerning strokes and other cardiovascular disease.
In a recent paper based on computer simulations of assumptions on associations between salt intake and BP, and between BP and mortality, it was concluded that a daily teaspoonful of salt (3 g) was a bigger health risk than cigarette smoking. 9 The sense of this conclusion can be judged by estimating the lack of accordance of these simulated projected effects with the abovementioned observed effects in populations. The reason for this lack of accordance is probably that the authors overestimated the assumed linear relationship between salt intake and BP and ignored the possibility that salt reduction may induce adverse effects. The present meta-analysis indicates that the adverse effect on lipids, especially triglyceride, is not just an acute effect as previously assumed, 16 but may be persistent also in longer-term studies. Furthermore, reduced sodium intake seems to harm patients with heart insufficiency and diabetes type 1 and 2. In all three patient groups reduced sodium intake is associated with increased mortality. [3] [4] [5] [6] The BP effect of reduced sodium intake has been related to age. Freedman and Petitti analyzed data from Intersalt 196 and found the paradox that along with the significant association between increase in BP with age and the salt excretion in urine, there was an inverse relationship between estimated BP and salt excretion in urine at age 20. Freedman stated that unless you preferred to conclude that salt should be eaten in high doses by youngsters and in reduced amounts by the elderly, the findings were probably due to uncontrolled confounding, not to variation in salt intake. 197 Furthermore, it is not clear whether the BP of different age cohorts in a cross-sectional study like Intersalt is representative of each other, and therefore the age/BP relationship may not be verified in a longitudinal study. 198 This position is confirmed by a study showing that recent birth cohorts attained lower BP than did earlier birth cohorts in the period 1887-1994. 199 According to this study based on data from >50,000 persons, it can be estimated that the median BP is ~15 mm Hg lower in a 50-year-old person from a recent birth cohort compared with a birth cohort from the late 19th century. Consequently there has been a dramatic fall in BP during the 20th century. In this context, the possible effect of sodium reduction of <1 mm Hg in normotensive persons calls for reflection. 200 In conclusion, low-vs. high-sodium diet in Caucasians with normal BP decreases BP <1%. A significant concomitant and persistent increase in plasma renin, plasma aldosterone and to a lesser degree of plasma adrenaline and plasma noradrenaline may contribute to the small effect of sodium reduction on BP. Furthermore, sodium reduction resulted in a significant increase in plasma cholesterol (2.5%) and plasma triglyceride (7%), which expressed in percentage, was numerically larger than the decrease in BP. The increase in triglyceride was numerically unchanged in studies with a duration of at least 2 weeks and in studies with sodium reduction to moderate levels of sodium intake. Due to the relatively small effects and due to the antagonistic nature of the effects (decrease in BP, increase in hormones and lipids), these results do not support that sodium reduction may have net beneficial effects in a population of Caucasians. In Caucasians with elevated BP, short-term sodium reduction decreases BP by ~2-2.5%, indicating that sodium reduction may be used as a supplementary treatment for hypertension. In Asians and blacks, the effect of sodium reduction was greater, but at present too few studies have been carried out to conclude different from that above.
